Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 4, 2013, Pages 385-391

  Krishnan, Arun V ^a   Kiernan, Matthew C ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Demyelination; Fampridine; Ion channel; Multiple sclerosis; Potassium channel; Sodium channel

Indexed keywords

4 AMINOPYRIDINE; POTASSIUM ION; SODIUM ION;

ASTHENIA; CHANNELOPATHY; DRUG EFFICACY; HUMAN; INSOMNIA; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; NERVE CONDUCTION; NERVE FIBER DEGENERATION; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; REVIEW; SUSTAINED RELEASE FORMULATION; WALKING SPEED;

EID: 84877850153     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512463769     Document Type: Review

References (49)

1. Waxman SG. Axonal conduction and injury in multiple sclerosis: The role of sodium channels. Nat Rev Neurosci 2006; 7: 932-941.
2. Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005; 57: 473-508. (Pubitemid 43036437)
3. Krishnan AV, Lin CSY, Park SB, et al. Axonal ion channels from bench to bedside: A translational neuroscience perspective. Prog Neurobiol 2009; 89: 288-313.
4. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71: 1134-1141.
5. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738.
6. Smith KJ. Sodium channels and multiple sclerosis: Roles in symptom production, damage and therapy. Brain Pathol 2007; 17: 230-242. (Pubitemid 46466142)
7. Trapp BD and Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder? Ann Rev Neurosci 2008; 31: 247-269.
8. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007; 204: 2363-2372. (Pubitemid 47529322)
9. Howell OW, Palser A, Polito A, et al. Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 2006; 129: 3173-3185. (Pubitemid 44871434)
10. Black JA, Newcombe J and Waxman SG. Astrocytes within multiple sclerosis lesions upregulate sodium channel Nav1.5. Brain 2010; 133: 835-846.
11. Craner MJ, Lo AC, Black JA, et al. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 2003; 126: 1552-1561. (Pubitemid 36834932)
12. Coman I, Aigrot MS, Seilhean D, et al. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain 2006; 129: 3186-3195. (Pubitemid 44871435)
13. Craner MJ, Hains BC, Lo AC, et al. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 2004; 127: 294-303. (Pubitemid 38160314)
14. Shields SD, Cheng X, Gasser A, et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann Neurol 2012; 71: 186-194.
15. Smith KJ, Kapoor R, Hall SM, et al. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49: 470-476. (Pubitemid 32281330)
16. Stys PK, Waxman SG and Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: Role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci 1992; 12: 430-439.
17. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489. (Pubitemid 43358068)
18. Kapoor R. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 2008; 274: 54-56.
19. Young EA, Fowler CD, Kidd GJ, et al. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008; 63: 428-435. (Pubitemid 351614708)
20. Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012; 135: 886-899.
21. Inglese M, Madelin G, Oesingmann N, et al. Brain tissue sodium concentration in multiple sclerosis: A sodium imaging study at 3 tesla. Brain 2010; 133: 847-857.
22. Rossi S, De Chiara V, Furlan R, et al. Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 2010; 24: 1379-1385.
23. Hammarstrom AK and Gage PW. Nitric oxide increases persistent sodium current in rat hippocampal neurons. J Physiol (Lond) 1999; 520 (Pt 2): 451-461. (Pubitemid 29511909)
24. Black JA, Liu S, Carrithers M, et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007; 62: 21-33. (Pubitemid 47235277)
25. Bechtold DA, Yue X, Evans RM, et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 2005; 128 (Pt 1): 18-28. (Pubitemid 40070516)
26. Margaretten NC, Hincks JR, Warren RP, et al. Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro. Toxicol Appl Pharmacol 1987; 87: 10-17. (Pubitemid 17004762)
27. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681-688.
28. Bostock H, Sears TA and Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol (Lond) 1981; 313: 301-315. (Pubitemid 11125577)
29. Lin CS, Krishnan AV, Park SB, et al. Modulatory effects on axonal function following intravenous immunoglobulin therapy in CIDP. Arch Neurol 2011; 68: 862-869.
30. Gu C and Gu Y. Clustering and activity tuning of Kv1 channels in myelinated hippocampal axons. J Biol Chem 2011; 286: 25835-25847.
31. Horresh I, Poliak S, Grant S, et al. Multiple molecular interactions determine the clustering of Caspr2 and Kv1 channels in myelinated axons. J Neurosci 2008; 28: 14213-14222.
32. Ivanovic A, Horresh I, Golan N, et al. The cytoskeletal adapter protein 4.1G organizes the internodes in peripheral myelinated nerves. J Cell Biol 2012; 196: 337-344.
33. Boyle ME, Berglund EO, Murai KK, et al. Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron 2001; 30: 385-397. (Pubitemid 32530583)
34. Sherratt RM, Bostock H and Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980; 283: 570-572. (Pubitemid 10136031)
35. Smith KJ, Felts PA and John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000; 123: 171-184. (Pubitemid 30037979)
36. Stefoski D, Davis FA, Faut M, et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71-77. (Pubitemid 17004147)
37. Davis FA, Stefoski D and Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: 186-192. (Pubitemid 20086640)
38. Bever CT Jr. The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 1994; 36 (Suppl): S118-S121. (Pubitemid 24220857)
39. Bever CT Jr, Anderson PA, Leslie J, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996; 47: 1457-1462. (Pubitemid 26422536)
40. van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992; 32: 123-130.
41. Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44: 1054-1059. (Pubitemid 24188176)
42. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: A randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007; 13: 357-368. (Pubitemid 46705997)
43. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687.
44. Krishnan A, Goodman A, Potts J, et al. Health-related quality of life is reduced in multiple sclerosis patients whose walking speed declines over time (P07.096). Neurology 2012; 78: P07.096.
45. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502.
46. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: What is a reliable change? Neurology 2002; 58: 1294-1296. (Pubitemid 34411881)
47. Goodman A. Updated analysis of open-label extension studies of dalfampridine extended release tablets in multiple sclerosis. Mult Scler 2011; 17: S245.
48. Jara M, Henney HR 3rd, Wessel T, et al. Dalfampridine extended release tablets: One year of post-marketing safety experience in the United States. Mult Scler 2011; 17: S216.
49. Hobart JC, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology 2003; 60: 31-36. (Pubitemid 36070640)